Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis


23 Nov 2019


Poster display session


Tumour Site

Colon and Rectal Cancer


Yijiao Chen


Annals of Oncology (2019) 30 (suppl_9): ix30-ix41. 10.1093/annonc/mdz421


Y. Chen1, W. Chang2, Y. Wei2, J. Xu3

Author affiliations

  • 1 Colorectal Cancer Center; Department Of General Surgery, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
  • 2 Colorectal Cancer Center; Department Of General Surgery, Zhongshan Hospital, Fudan University, 200010 - shanghai/CN
  • 3 General Surgery, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 93P


New predictive biomarkers for cetuximab-resistance for patients with RAS wild-type colorectal liver metastases (CRLM).


216 patients with initially unresectable liver-limited RAS wild-type CRLM were identified from previous clinical studies. Among these patients, 103 patients received chemotherapy (mFOLFOX6 or FOLFIRI) plus cetuximab, and 113 received chemotherapy alone as first-line treatment. Next-generation sequencing of primary tumors was done for single nucleotide polymorphism according to custom panel. The patients receiving cetuximab-based chemotherapy were divided into two groups: one group was cetuximab-resistant group and the other group was cetuximab-sensitive group. Potential predictive biomarkers were determined by “random forest" machine learning.


Ten potential predictive genes, namely RET, PTPN11, FLT3, AKT1, ACTN4, ERBB4, FGFR3, MDC1, CUL9, and ZNF462, were identified. In the cohort of cetuximab-based chemotherapy, patients with all-wild-type genes had markedly improved median progression-free survival (12.0 vs. 4.0 months, P < 0.0001) and overall survival (37.0 VS. 24.0 months, P < 0.0001) compared with those with gene mutation; In the cohort of at-least-one gene mutation, patients receiving chemotherapy alone had comparable median PFS (4.0 VS. 4.0 months, P = 0.9498). Moreover, mutated are more common in patients with right-sided colon cancer.


Ten new predictive mutations help to refine the selection of RAS and BRAF wild-type metastatic colorectal cancer patients candidates for anti-EGFRs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Zhongshan Hospital.


The National Natural Science Foundation of China.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.